Patients with advanced estrogen receptor-positive, HER2-negative breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from nonresponders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early timepoints as prognostic markers.
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
Annals of Oncology | | A. Mamann, Y. Pradat, F.C. Bidard, S. Delaloge, L. Cabel, I. Faull, S. Marques, T. Bachelot, F. Dalenc, T. de la Motte Rouge, B. Pistilli, J. Samaniego, J.S. Frenel, C. Levy, J.M. Ferrero, R. Sabatier, S. Ladoire, C. Chakiba, A.C. Hardy, J. Lemonnier, Y. Mahi, F. Andre, P.H. Cournede, S. Michiels, E. Bernard
Topics: breast-cancer, targeted-therapy, new-technology